OTC · Health care

Burzynski Research Institute Inc (BZYR)

It posted a net loss of $1.3M. At November 30, 2025 it held $2.2K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on January 13, 2026.

Watch BZYR in 60 seconds

Price

$0.00

0.00% on the day · September 25, 2026

52-week range $0.00 to $0.05

Market cap

$262.9K

What Burzynski Research Institute Inc does

Burzynski Research Institute Inc is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on OTC under the ticker BZYR.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$0	-$1.4M	-$1.4M	-$0.01	n/a
2024	$0	-$1.3M	-$1.3M	-$0.01	n/a
2023	$0	-$916.3K	-$916.3K	-$0.01	n/a
2022	$0	-$976.7K	-$976.7K	-$0.01	n/a
2021	$0	-$1.3M	-$1.2M	-$0.01	n/a
2020	$0	-$1.6M	-$1.6M	-$0.01	n/a

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Burzynski Research Institute Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

May 12, 2026
Other event 8-K
April 23, 2026
Executive or director change 8-K
January 13, 2026
Quarterly report 10-Q · period to November 30, 2025Diluted EPS $0.00 versus $0.00.
October 14, 2025
Quarterly report 10-Q · period to August 31, 2025Diluted EPS $0.00 versus $0.00.
September 11, 2025
Auditor change 8-K/A
July 24, 2025
Auditor change 8-K
July 15, 2025
Quarterly report 10-Q · period to May 31, 2025Diluted EPS $0.00 versus $0.00.
May 20, 2025
Annual report 10-K · period to February 28, 2025Diluted EPS -$0.01 versus -$0.01.
January 13, 2025
Quarterly report 10-Q · period to November 30, 2024Diluted EPS was $0.00.
October 10, 2024
Quarterly report 10-Q · period to August 31, 2024Diluted EPS was $0.00.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on October 6, 2021. Insider transactions on SEC

All filings on SEC EDGAR

Questions about BZYR

What does Burzynski Research Institute Inc do?

Burzynski Research Institute Inc is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on OTC under the ticker BZYR.

Is Burzynski Research Institute Inc profitable?

No. Over the twelve months to November 30, 2025 it reported a net loss of $1.3M.

When did Burzynski Research Institute Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on January 13, 2026. It covers the period to November 30, 2025. Its newest filing of any kind is the other event from May 12, 2026.

Similar companies

IDXX

Idexx Laboratories Inc

QDEL

QuidelOrtho Corp

LNTH

Lantheus Holdings, Inc.

Intellia Therapeutics, Inc.

Compare BZYR with

Compare BZYR with any company

Follow BZYR

Get an email when Burzynski Research Institute Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow BZYR: get an email when it files

Where the numbers come from

Financial figures are the values Burzynski Research Institute Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.